» Articles » PMID: 30462710

Association Between Sleep-disordered Breathing and Breast Cancer Aggressiveness

Abstract

Background: Sleep-disordered breathing (SDB) has been associated with cancer aggressiveness, but studies focused on specific tumors are lacking. In this pilot study we investigated whether SDB is associated with breast cancer (BC) aggressiveness.

Methods: 83 consecutive women <65 years diagnosed with primary BC underwent a home respiratory polygraphy. Markers of SDB severity included the apnea-hypopnea index (AHI) and the 4% oxygen desaturation index (ODI4). The Ki67 proliferation index, lack of hormone receptors (HR-), Nottingham Histological Grade (NHG), and tumor stage were used as markers of BC aggressiveness. The association between SDB and molecular subtypes of BC was also assessed.

Results: The mean (SD) age was 48.8 (8.8) years and body mass index was 27.4 (5.4) Kg/m2. 42 women (50.6%) were post-menopausal. The median (IQR) AHI was 5.1 (2-9.4), and ODI4 was 1.5 (0.5-5.8). The median (IQR) AHI did not differ between the groups with Ki67>28% and Ki67<29% [5.1 (2.6-8.3) vs 5.0 (1.5-10), p = 0.89)], HR- and HR+ [5.7 (1.6-12.4) vs 4.9 (2-9.4), p = 0.68], NHG (Grade3, Grade2, and Grade1; p = 0.86), tumor stage (stage III-IV, stage II, and stage I; p = 0.62), or molecular subtypes (Luminal A, Luminal B, HER2, and triple negative; p = 0.90). The prevalence of an AHI≥5 did not differ between the groups with Ki67>28% and Ki67<29% (51.2% vs 52.3%, p = 0.90), HR- and HR+ (58.3% vs 49.1%, p = 0.47), NHG categories (p = 0.89), different tumor stages (p = 0.71), or molecular subtypes (p = 0.73). These results did not change when the ODI4 was used instead of the AHI.

Conclusion: Our results do not support an association between the presence or severity of SDB and BC aggressiveness.

Citing Articles

PSGL-1: a novel immune checkpoint driving T-cell dysfunction in obstructive sleep apnea.

Diaz-Garcia E, Garcia-Sanchez A, Alfaro E, Lopez-Fernandez C, Manas E, Cano-Pumarega I Front Immunol. 2023; 14:1277551.

PMID: 37854605 PMC: 10579800. DOI: 10.3389/fimmu.2023.1277551.


Screening for obstructive sleep apnoea in post-treatment cancer patients.

Subramanian H, Fuchsova V, Elder E, Brand A, Howle J, DeFazio A Cancer Rep (Hoboken). 2022; 6(3):e1740.

PMID: 36512174 PMC: 10026305. DOI: 10.1002/cnr2.1740.


Cancer sleep symptom-related phenotypic clustering differs across three cancer specific patient cohorts.

Kairaitis K, Madut A, Subramanian H, Trivedi R, Man H, Mather M J Sleep Res. 2022; 31(5):e13588.

PMID: 35470503 PMC: 9788230. DOI: 10.1111/jsr.13588.


The Association of Obstructive Sleep Apnea With Breast Cancer Incidence and Mortality: A Systematic Review and Meta-analysis.

Yap D, Tan N, Tan B, Teo Y, Tan V, See A J Breast Cancer. 2022; 25(3):149-163.

PMID: 35380020 PMC: 9250875. DOI: 10.4048/jbc.2022.25.e11.


Association of obstructive sleep apnea and nocturnal hypoxemia with all-cancer incidence and mortality: a systematic review and meta-analysis.

Tan B, Teo Y, Tan N, Yap D, Sundar R, Lee C J Clin Sleep Med. 2021; 18(5):1427-1440.

PMID: 34755597 PMC: 9059590. DOI: 10.5664/jcsm.9772.


References
1.
Chiner E, Arriero J, Signes-Costa J, Marco J, Fuentes I . [Validation of the Spanish version of the Epworth Sleepiness Scale in patients with a sleep apnea syndrome]. Arch Bronconeumol. 1999; 35(9):422-7. DOI: 10.1016/s0300-2896(15)30037-5. View

2.
Kakizaki M, Kuriyama S, Sone T, Ohmori-Matsuda K, Hozawa A, Nakaya N . Sleep duration and the risk of breast cancer: the Ohsaki Cohort Study. Br J Cancer. 2008; 99(9):1502-5. PMC: 2579702. DOI: 10.1038/sj.bjc.6604684. View

3.
Coates A, Winer E, Goldhirsch A, Gelber R, Gnant M, Piccart-Gebhart M . Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015; 26(8):1533-46. PMC: 4511219. DOI: 10.1093/annonc/mdv221. View

4.
Chen A, Sceneay J, Godde N, Kinwel T, Ham S, Thompson E . Intermittent hypoxia induces a metastatic phenotype in breast cancer. Oncogene. 2018; 37(31):4214-4225. DOI: 10.1038/s41388-018-0259-3. View

5.
Liu L, Liu W, Wang L, Zhu T, Zhong J, Xie N . Hypoxia-inducible factor 1 mediates intermittent hypoxia-induced migration of human breast cancer MDA-MB-231 cells. Oncol Lett. 2017; 14(6):7715-7722. PMC: 5727604. DOI: 10.3892/ol.2017.7223. View